Incidence and management of bevacizumab-related toxicities in colorectal cancer
about
Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degenerationValue of bevacizumab in treatment of colorectal cancer: A meta-analysisSafety of bevacizumab in patients with advanced cancer: a meta-analysis of randomized controlled trials.ELLIPSE Study: a Phase 1 study evaluating the tolerance of bevacizumab nasal spray in the treatment of epistaxis in hereditary hemorrhagic telangiectasiaLate-Onset Pulmonary Fistula after Resection of Pulmonary Metastasis from Colorectal Cancer Following Perioperative Chemotherapy with Bevacizumab.Thrombotic events in metastatic colorectal cancer patients treated with leucovorin, fluorouracil and irinotican (FOLFIRI) plus bevacizumab.Noncardiac vascular toxicities of vascular endothelial growth factor inhibitors in advanced cancer: a reviewIntraarticular hemorrhage due to bevacizumab in a patient with metastatic colorectal cancer: a case report.Vascular endothelial growth factor pharmacogenetics: a new perspective for anti-angiogenic therapy.Evidence for the role of bevacizumab in the treatment of advanced metastatic breast cancer: a review.Timing of administration of bevacizumab chemotherapy affects wound healing after chest wall port placement.Tolerability profile of bevacizumab in metastatic colorectal cancer: about a Medical Department experience.Tumor control versus adverse events with targeted anticancer therapies.Complications of subspecialty ophthalmic care: systemic complications from the intravitreal administration of agents that target the vascular endothelial growth factor pathway.Increased rates of local complication of central venous catheters in the targeted anticancer therapy era: a 2-year retrospective analysis.Massive choroidal hemorrhage after intravitreal administration of bevacizumab (Avastin) for AMD followed by controlateral sympathetic ophthalmia.Effects of intraperitoneal bevacizumab administration on colonic anastomosis and early postoperative adhesion formation.Renal function after intravitreal administration of vascular endothelial growth factor inhibitors in patients with diabetes and chronic kidney disease.Posterior reversible encephalopathy syndrome (PRES) after bevacizumab therapy for metastatic colorectal cancer.
P2860
Q24193614-66ACBDE6-944B-4F1D-95F3-05086E153224Q26849789-D6C47F1B-E55E-4881-9C65-B8601A2A269EQ33392652-1C6C5F27-93B9-4029-9307-44EB77C061F6Q33573626-542D7664-DD00-4395-B13F-C2761D25EEE3Q33832694-3794E061-90EF-4897-B736-3994915D5504Q35419411-9B98A202-142A-4830-97AA-FC637DF6C138Q35584543-027ECF8B-C7B7-4AC2-A8D1-79B592838BFAQ36299126-6D1B1621-F23B-4583-922D-8B5D128E0650Q36691776-F47AF018-07D2-4D5E-9118-134687600783Q37355708-9C5FD329-E962-4508-AFCD-B9D0713706CBQ37406167-4A01CDD7-D3F5-4F99-9AB9-802D09B41B08Q37665798-4CE48EBA-6785-45DB-8DFB-27B1D36065AAQ37969899-3E0DE532-75C5-4E6D-AFA0-F051F13A6E55Q38261105-C970D563-8A9E-4879-9ECA-CAF221864C8AQ41696585-74942B3E-FC59-4180-8312-243402EB6A11Q42004970-C98F305F-CCD9-40A7-A564-C754D3C78CC1Q44487884-49B59BCC-2DD7-447B-B301-9A94FD42760AQ47649428-008B0577-0453-4E07-B0D8-0951269022F6Q55174130-28CC0B0F-9D27-4C45-A3E2-672EB6942E70
P2860
Incidence and management of bevacizumab-related toxicities in colorectal cancer
description
2006 nî lūn-bûn
@nan
2006 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Incidence and management of bevacizumab-related toxicities in colorectal cancer
@ast
Incidence and management of bevacizumab-related toxicities in colorectal cancer
@en
Incidence and management of bevacizumab-related toxicities in colorectal cancer
@nl
type
label
Incidence and management of bevacizumab-related toxicities in colorectal cancer
@ast
Incidence and management of bevacizumab-related toxicities in colorectal cancer
@en
Incidence and management of bevacizumab-related toxicities in colorectal cancer
@nl
prefLabel
Incidence and management of bevacizumab-related toxicities in colorectal cancer
@ast
Incidence and management of bevacizumab-related toxicities in colorectal cancer
@en
Incidence and management of bevacizumab-related toxicities in colorectal cancer
@nl
P2860
P356
P1476
Incidence and management of bevacizumab-related toxicities in colorectal cancer
@en
P2093
M Wasif Saif
Ranee Mehra
P2860
P304
P356
10.1517/14740338.5.4.553
P407
P577
2006-07-01T00:00:00Z